Dr. Myriam Mendila

Company: CureVac

Job title: Chief Scientific Officer and Head of R&D

Seminars:

Current Cancer Vaccine Strategies Including Initial Phase 1 Study Data of CVGBM, an Off-the-Shelf Cancer Vaccine in Glioblastoma 9:30 am

Cancer vaccines based on mRNA technologies have shown encouraging clinical data over the last couple of years Showcasing current strategies to develop cancer vaccines focus on either personalized cancer vaccines or off-the-shelf cancer vaccines Presenting CVGBM, an off-the-shelf cancer vaccine, that demonstrated encouraging immunogenicity in a phase 1 study in patients with GBM after tumor…Read more

day: Day One